Use of Bisphosphonates in the Treatment of Osteopathy After Liver Transplantation
Status
Conditions
Treatments
Details and patient eligibility
About
Patients with a terminal chronic liver disease have a disordered bone metabolism resulting in a higher risk of falling ill with osteoporosis. Although liver transplantation restores liver function, immunosuppressive therapy (especially corticosteroids) after transplantation increases again the risk of osteoporosis and bone fragility. Zoledronate, a bisphosphonate, slows down the destruction of bone. The purpose of this study is to determine whether bisphosphonates are effective in the prevention of osteoporosis following immunosuppressive therapy after liver transplantation.
Sex
Ages
Volunteers
Inclusion criteria
- primary liver transplantation
- retransplantation within two weeks
- written informed consent
- Age ≥ 18 years
Exclusion criteria
- chronic kidney disease:
- Creatinine Clearance < 35 ml/min or Serum Creatinine > 2,5 mg/dl
- known hypersensitivity to Zoledronate, or any of the recipients of the drug
- bone specific medication (Bisphosphonate, Fluoride, Calcitonin) within the last three months before liver transplantation
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal